Connect Biopharma (CNTB) announced that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical, has submitted its New ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in ...

New data reveals sponsors risk wasting billions by designing overly complex trials and repeatedly recruiting from oversaturated investigator sites Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a ...

On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) soared 24% in Monday’s session following encouraging results from its Phase ...